Innova Medical Group, Inc. – FDA 483, Apr 9, 2021
An FDA inspection of INNOVA MEDICAL GROUP, INC. in Pasadena, CA, revealed extensive quality system deficiencies related to their SARS-CoV-2 Antigen Rapid Qualitative Test system. The firm lacked established procedures for critical operations including device control, acceptance activities, nonconforming product management, supplier evaluation, corrective and preventive actions, complaint handling, and Medical Device Reporting. These widespread issues indicate a severely underdeveloped quality system, posing a high risk to product quality and regulatory compliance.
ID · 7de12bad-05ac-4c25-a991-e1e154dd6ca6
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.